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Abstract
Background: Postoperative pain and, in a more extended perspective, quality of recovery (QOR) should be considered
the principal endpoints after day surgery. Non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol are a
cornerstone of pain treatment after painful day surgery. Nevertheless, NSAIDs are not always sufficiently effective,
have numerous contraindications, and consequently are not suitable in up to 25 % of all patients. Metamizole is a
non-opioid compound with a favourable gastrointestinal, cardiovascular and cerebrovascular profile compared to
NSAIDs. The aim of this study is to assess if a combination of metamizole and paracetamol is non-inferior to a
combination of ibuprofen and paracetamol in the treatment of acute postoperative pain at home after painful
day case surgery. In addition, we aim to assess and compare quality of recovery (QOR) profiles of both groups.
Methods/Design: This is an investigator-initiated, double-blind, randomised controlled, non-inferiority trial. A total of
200 patients undergoing elective haemorrhoid surgery, arthroscopic shoulder or knee surgery, or inguinal hernia repair
in a day care setting will be randomised to receive either a combination of metamizole and paracetamol (MP) or
a combination of ibuprofen and paracetamol (IP). Participants will take study medication orally for 4 days. Primary
endpoints are average postoperative pain intensity measured by an 11-point Numeric Rating Scale at postoperative
day 1 and QOR profile measured by the Functional Recovery Index (FRI), the 1-item Global Surgical Recovery (GSR)
index and the EuroQol (EQ-5D) questionnaire at days 1, 2, 3, 4, 7, 14 and 28 postoperatively. Secondary outcomes
include compliance with study medication, adverse effects of study medication, use of rescue medication and
satisfaction with study medication, surgery and hospital care and telephone follow-up.
Discussion: This study will provide clinical evidence on the analgesic efficacy and safety of a combination of
metamizole and paracetamol in treating postoperative pain at home after painful day surgery. This study may
also provide an insight into QOR profile after four different types of surgery and into the interrelationship between
three different instruments used to assess QOR.
Trial status: Recruitment is currently ongoing.
Trial registration: European Union Clinical Trials Register 2015-003987-35. Registered 10 November 2015.
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Background
Day surgery has been expanding substantially in the past
decade, primarily because it is associated with lower
costs and it is believed to be as safe as surgery in the in-
patient setting. Moreover, it seems that early discharge
can contribute to faster recovery and a decreased inci-
dence of hospital-associated complications.
In view of the relative absence of major complications,
postoperative pain and, in a more extended perspective,
quality of recovery (QOR) should be considered the prin-
cipal endpoints after day surgery [1–3]. Pain and QOR are
two related phenomena encompassing many dimensions
in physical, psychological and social health [4].
Particularly in the ambulatory setting, good postopera-
tive analgesia is challenging because patients have to
control pain at home by themselves [5] and the types of
analgesics (i.e. no strong opioids) as well as the route of
administration (i.e. no epidural, intravenous, subcutane-
ous or intramuscular route) is limited compared to the
inpatient setting. Despite increased awareness and im-
provements in postoperative pain management over the
last decades, the prevalence of outpatients suffering
moderate to severe acute postoperative pain at home
still remains high and varies from 9 to 40 % [6–10].
More specific, patients undergoing haemorrhoid surgery,
arthroscopic shoulder and knee surgery, and inguinal
hernia repair seem to be at highest risk to develop moder-
ate to severe pain and to be poorly recovered on the fourth
postoperative day [3, 8].
Another major disadvantage of the ambulatory setting
is related to the absence of postoperative surveillance by
professionals. The latter implicates that the individual
patient has to assess, without any support, if his/her
QOR is normal or not. Unfortunately, there is rather
limited information on procedure-specific QOR after
day surgery in a more protracted perspective [3, 4, 11].
It is of major importance to study QOR profiles after
different types of day surgery. This knowledge would
allow discriminating between a normal and pathological
health trajectory. Furthermore, the role and effect of
pain therapy on QOR profile should be more closely
investigated.
Nowadays, a multimodal approach to control pain has
been advocated in the ambulatory setting. This approach
is based on a combination of paracetamol, non-steroidal
anti-inflammatory drugs (NSAIDs), weak opioids, and
local and regional anaesthesia has been advocated in the
ambulatory setting [7, 12, 13]. Furthermore a systematic
meta-analysis has shown that a combination of paraceta-
mol and an NSAID may offer superior analgesia compared
to either drug alone [14]. Consequently, ibuprofen, a
non-steroidal anti-inflammatory drug (NSAID) with a
favourable analgesic profile [15] in combination with
paracetamol comprise our standard multimodal pain
treatment model for patients at home after painful day
surgery. Nevertheless, NSAIDs are not always sufficiently
effective [8], have numerous contraindications [16–20],
and as a result of this are not suitable in up to 25 % of all
patients [21].
Metamizole or dipyrone is a non-opioid compound with
potent analgesic, antipyretic and spasmolytic effects [22].
The analgesic efficacy of intravenous or intramuscular
metamizole for pain relief after inpatient surgery is well
described [23–29]. The analgesic efficacy of individual
tramadol, metamizole and paracetamol for postoperative
analgesia at home after ambulatory hand surgery has
also been analysed [30]. However, the analgesic efficacy
of a combination of paracetamol and metamizole for
pain relief at home after day surgery has never been
studied.
Hence, in the present study we aim to assess if a com-
bination of metamizole and paracetamol is non-inferior
to a combination of the NSAID ibuprofen and paraceta-
mol in the treatment of acute postoperative pain at
home after painful day case surgery. We hypothesise that
ambulatory patients postoperatively treated with para-
cetamol/metamizole will achieve equal or even better
pain relief compared to patients treated with paraceta-
mol/ibuprofen. In addition, we aim to assess and com-
pare QOR profiles of both groups. We hypothesise that
each type of day surgery included in our trial will have a
unique QOR profile, significantly different from the
QOR profile of other types of day surgery.
Methods
Study design
This is an investigator-initiated, double-blind, rando-
mised controlled, non-inferiority trial. The study is
being performed in accordance with the Declaration of
Helsinki and has been approved by the ethics committee
of the JESSA Hospital Hasselt (registration number
15.105/pijn15.02) and by the European Union Drug
Regulating Authorities Clinical Trials (EudraCT Num-
ber 2015-003987-35). Informed consent will be ob-
tained from all participants. The final report will follow
the CONSORT 2010 guidelines as well as the extension
to non-inferiority trials.
Population
Consecutive adult patients undergoing elective haemor-
rhoid surgery, arthroscopic shoulder or knee surgery, or
inguinal hernia repair in a day care setting will be in-
formed about the study on their preoperative visit by the
surgeon and they will be provided with a patient infor-
mation sheet.
Patients will be assessed for eligibility on arrival at the
outpatient clinic. Detailed eligibility criteria are listed in
Table 1. The purpose, procedures, and potential risks
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and benefits of the study will be explained thoroughly to
all participants who meet the eligibility criteria by a
trained resident physician or study nurse. If interested, a
written informed consent will be obtained from each
participant prior to randomisation. The participants will
be able to withdraw from the study at any time without
consequences for therapy. This trial will be performed at
a high-volume institution (JESSA Hospital, Hasselt,
Belgium). Based on the number of selected procedures
performed annually in the JESSA hospital, it is estimated
that the trial will be executed from 28 January 2016 to
January 2017, including enrollment and follow-up.
Interventions
After obtaining written informed consent, patients will be
randomised in a 1:1 ratio to either of the two study
groups: a combination of metamizole and paracetamol
(MP) or a combination of ibuprofen and paracetamol (IP)
group. Patients in the MP group (experimental arm) will
be instructed to take metamizole 1 g orally three times a
day for 4 days and patients in the IP group (control arm)
will be instructed to take ibuprofen 600 mg orally three
times a day for 4 days. All patients will also be treated with
paracetamol 1 g orally four times a day during the entire
study period. The first dose of study medication (metami-
zole and paracetamol (MP) or ibuprofen and paracetamol
(IP) will be given 30 minutes before surgery. Rescue medi-
cation consists of tramadol 50 mg orally and will be taken
up to three times a day only if pain relief was not satisfac-
tory with the study medication. Patients will be instructed
to take their trial medication as prescribed and will be
provided with a detailed medication schedule. Further-
more, they will be called by telephone daily and asked if
they took their trial medication as prescribed.
Perioperative procedure
All patients scheduled for an arthroscopic shoulder pro-
cedure will receive an interscalene block preoperatively.
In addition, general anaesthesia will be induced with
intravenous (IV) alfentanil 10 mcg/kg IV sufentanil
0.15 mcg/kg and IV propofol 2 mg/kg. Patients under-
going arthroscopic shoulder surgery or laparoscopic
inguinal hernia repair will also receive rocuronium 20–
40 mg before endotracheal intubation. A laryngeal
mask airway will be inserted in all other patients. An-
aesthesia will be maintained with sevoflurane in a mix-
ture of 50:50 air/oxygen. Before the end of surgery, all
patients will receive ondansetron 4 mg IV. Further-
more, wound infiltration with local anaesthesia (bupi-
vacaine 0.5 %) will be performed in all patients except
those receiving an interscalene block. Duration of
surgery will be recorded.
Postoperatively, all patients will be treated with subse-
quent bolus injections of piritramide 2 mg intravenously
until a Numeric Rating Scale (NRS) ≤3 is reached/
achieved in the Post-Anaesthesia Care Unit (PACU). Be-
fore hospital discharge, patients will receive the study
medication and instructions for use. Dropout criteria are
surgical complications leading to either resurgery or
unanticipated hospital admission.
Outcome measures
Outcome measures will be assessed at baseline and by
telephone call at day 0, 1, 2, 3, 4, 7, 14 and 28 postopera-
tively. Several attempts at different times will be re-
peated in case of an initial unsuccessful call attempt.
Outcomes in the domains of pain, QOR, compliance
with study medication and patient satisfaction will be
assessed (Fig. 1).
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
- Patients aged between 18 and 70 years
- ASA classification 1, 2 or 3
- Body weight > 50 kg




• Inguinal hernia repair
- Not meeting inclusion criteria
- Cognitive impairment or no understanding of the Dutch language
- Preoperative pharmacologic pain treatment and/or a history of chronic pain
- Allergy to or a contraindication for taking the study medication (e.g. paracetamol,
metamizole, ibuprofen or another non-steroidal anti-inflammatory drug)
- Porphyria
- Pregnancy or lactation
- A history of severe renal, hepatic, pulmonary, or cardiac failure
- Current symptoms or a history of gastrointestinal bleeding
- Ileus or chronic obstipation




- Use of anti-rheumatic drugs
- Rhinosinusitis or nasal polyposis
- Glucose-6-phosphate dehydrogenase deficiency
- Fever or other signs of infection
- For patients undergoing arthroscopy shoulder:
refusal of an interscalene block
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Primary outcome measures
Primary endpoints are:
1. Average postoperative pain intensity measured by
an 11-point Numeric Rating Scale (NRS; where
0 = no pain, and 10 = worst pain imaginable) at
postoperative day 1.
2. QOR profile measured by the Functional Recovery
Index (FRI) [1], the 1-item Global Surgical Recovery
(GSR) index [31] and the 5-dimensional European
Quality of Life (EQ-5D) questionnaire [32] at days 1,
2, 3, 4, 7, 14 and 28 postoperatively.
 The convenient and also validated GSR index
represents a single question about the extent to
which patients considered themselves to be
recovered from the surgery (0–100 %) [31].
 The FRI is a questionnaire-based instrument
specifically developed to assess post-discharge
functional QOR after day surgery and covers
14 items grouped under three factors (pain and
social activity, lower limb activity and general
physical activity) [1].
 The 5-dimensional EQ-5D is a non-disease-
specific instrument developed for describing
Fig. 1 Schedule of enrollment, interventions and assessments
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and valuing health-related quality of life [32] and
has already been used to assess intermediate
(4 days) and late (2 weeks to 6 months) quality
of recovery after day surgery [3, 33, 34].
Secondary outcome measures
The following outcomes will also be assessed (see also
Fig. 1):
 Postoperative pain intensity at movement and rest
measured by an 11-point Numeric Rating Scale
(NRS; where 0 = no pain, and 10 = worst pain
imaginable) at discharge and day 1, 2, 3, 4, 7, 14
and 28 postoperatively.
 Average postoperative pain intensity measured by an
11-point Numeric Rating Scale (NRS; where 0 = no
pain, and 10 = worst pain imaginable) at day 0, 2, 3,
4, 7, 14 and 28 postoperatively.
 Adherence to study medication at day 1, 2, 3 and 4
postoperatively.
– Definition compliance: full compliance: analgesia
use as prescribed “Yes”, no compliance: analgesia
use as prescribed “No”.
 Adverse effects of study medication (i.e. pyrosis,
signs of agranulocytosis or thrombocytopenia)
 Total postoperative intravenous piritramide
consumption at the PACU (milligram)
 Use of rescue medication (tramadol at home) at
day 1, 2, 3 and 4 postoperatively (yes/no).
 Satisfaction with study medication, surgery and
hospital care and telephone follow-up measured
at the seventh postoperative day by an 11-point
Numeric Rating Scale (NRS).
Baseline assessment measurements
In addition to the primary and secondary outcome mea-
sures, the researcher will also record participants’: age,
gender, body mass index (BMI), ASA classification, work
status, highest level of education, fear of the surgical
procedure (using an 8-item surgical fear questionnaire)
[3, 35], preoperative pain (the baseline NRS score), ex-
pected pain (NRS score), baseline GSR, FRI and EQ-5D,
and the history of (related) surgery.
Safety assessments
All possible adverse effects (AEs) of study medication
will be explained thoroughly to all patients who meet
the eligibility criteria. All participants will be questioned
about adverse events at each telephone call (day 1, 2, 3,
4, 7, 14 and 28 postoperatively). Patients will be specific-
ally asked whether they experienced postoperative nau-
sea and vomiting, pyrosis or stomach ache, obstipation,
anaphylaxis, fever, chills, mouth ulcers, a sore throat or
signs of infection, petechiae and bleeding diathesis.
Furthermore, patients are instructed to contact a research
assistant immediately by phone if they experience mod-
erate to severe signs of infection and/or bleeding diath-
esis. A complete blood count will then be performed to
exclude leukopenia, anaemia and thrombocytopenia
and trial medication will be withdrawn from the pa-
tient. Such an event will be reported as a serious
adverse event (SAE).
Randomisation and blinding
Participants will be randomly assigned to the MP or
the IP group using a computer-generated random al-
location sequence, created by the study statistician.
Randomisation will be stratified for type of surgery.
Each patient will receive a unique randomised test
number corresponding to the specified drug, accord-
ing to the group allocation. The randomisation list re-
mains with the study statistician and the hospital
pharmacy for the whole duration of the study. Hence,
the patients participating in the trial, the treating
physicians, the researchers dispensing the medication
and assessing outcomes (i.e. four trained resident phy-
sicians and one study nurse) and the data managers
will be blinded for group allocation. For test drug
blinding, the metamizole tablets and the ibuprofen
tablets will be made to be visually lookalike. Further-
more, the hospital pharmacy will package study medi-
cation into identical blister containers. Each container
will be numbered according to the randomisation list.
Only adverse events (AEs) that are considered serious,
unexpected and at least possibly related to the medi-
cation would have to be unblinded.
Sample size
The primary outcome measures are the average postop-
erative pain intensity measured by an 11-point Numeric
Rating Scale (NRS) on the first postoperative day as
well as the QOR profile. As QOR profile is strongly in-
fluenced by postoperative pain intensity, sample size
calculation will be based on expected postoperative
pain intensity. Based on previous studies, we assume a
standard deviation of the NRS scores of 2.5 on the first
postoperative day and 1.7 on the fourth postoperative
day [3, 5]. A difference in mean average NRS score of 1
point or less is considered non-inferior. Therefore, the
present study must have the power to detect a differ-
ence of more than 1 point to reject the null hypothesis
that the analgesic power of a combination of metami-
zole and paracetamol is inferior compared to a combin-
ation of ibuprofen and paracetamol. Based on these
assumptions, we will require 78 patients in each group
to have a power of at least 80 % (β = 0.2). To determine
non-inferiority, we will compute 95 % confidence inter-
vals for the difference in primary endpoints. The
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sample size will be inflated to 100 participants per
group (200 in total) to account for a possible 22 % loss
to follow-up.
Data management and statistical analysis
Participants’ data will be recorded in individual partici-
pant record booklets. Coded, depersonalised data will be
entered into a web-based questionnaire (Questback) and
then exported to SPSS version 21 (IBM Corp, Armonk,
NY, USA). Database access will be restricted to the
authorised research team. Participants’ study information
will not be released outside of the study without the
written permission of the participant.
All primary and secondary endpoints will be analysed
on a per protocol basis according to a non-inferiority
design. As a sensitivity analysis, we will compare these
results to an intention-to-treat analysis. Data will be pre-
sented as mean values +/- SD, numbers (n), and percent-
ages (%). P values < 0.05 will be considered statistically
significant. Missing baseline values will be imputed using
multiple imputation. The number of imputations will be
set to 10. To determine non-inferiority for the difference
in NRS score on the first day after surgery, we will com-
pute 95 % confidence intervals. The QOR profiles will
be assessed using linear mixed models, taking time, type
of surgery and group assignment into account. Differ-
ences between the groups on secondary outcomes will
be analysed using the Student’s t test for continuous out-
comes, except for the pain scores, since these are often
heavily skewed. For those outcomes, we will use the
Mann-Whitney U test. All categorical variables will be
compared using Pearson’s χ2 test. For multivariate analysis
the following potential confounders will be assessed: surgi-
cal fear, preoperative pain (baseline NRS), expected pain,
baseline FRI and EQ-5D, age, sex, work status, educational
level, ASA classification, BMI, history of related surgery,
type of surgery, and duration of surgery. In addition,
changes in the QOR scores over time in the postoperative
period will be analysed using linear mixed models
and we will use logistic regression to explore possible
predictors for QOR. All analyses will be performed
using SPSS version 21.
Monitoring
Data Monitoring Committee (DMC)
The major task of the DMC is safety monitoring. Any
SAE or suspected unexpected serious adverse reaction li-
able to produce disability or deformity is an indication
to set up a DMC meeting. Members of the DMC are (1)
head of the Department of Hematology of the JESSA
Hospital Hasselt and (2) the primary statistician of the
trial. The advice of the DMC will be notified by the re-
search committee to the ethics committee of the JESSA
Hospital Hasselt that approved the protocol. Interim
analyses will not be performed by the DMC to mitigate
possible bias and preserve trial integrity.
Procedures for recording and reporting adverse events
Adverse events (AEs) will be recorded and severity and
relation to study participation will be assessed. SAE data
will be collected and handled by the DMC.
Discussion
This study will provide clinical evidence on the analgesic
efficacy and safety of a combination of metamizole and
paracetamol in treating postoperative pain at home after
painful day surgery.
Metamizole was first marketed in Germany in 1922
[36]. The molecular mechanism of analgesic and antipyr-
etic action of metamizole however, is still not fully
understood. Metamizole is a prodrug and its activity is
due to its immediate conversion to its active metabolites
[37]. Several mechanisms were proposed, including the
involvement of endogenous opioids and COX-1/COX-2
inhibition by dipyrone and its metabolites [38, 39]. Re-
cently, there is growing evidence that also the endocan-
nabinoid/endovanilloid system plays a role in the effects
of metamizole against pain [36, 37, 40, 41]. It has been
additionally emphasised that co-administration of trama-
dol and dipyrone results in an important potentiation of
their individual anti-nociceptive effects [42, 43]. Another
important advantage of metamizole is the favourable
gastrointestinal [44, 45], cardiovascular and cerebrovascu-
lar profile compared to NSAIDs [16–20]. Consequently,
the excess mortality due to agranulocytosis, aplastic an-
aemia, anaphylaxis and serious gastrointestinal complica-
tions was found to be in favour of metamizole compared
to the NSAID diclofenac (25 per 100 million vs 592
per 100 million) [46].
In contrast, use of metamizole is under debate and is
even restricted in many countries due its association
with agranulocytosis. This restriction is based on two
studies who found a very high incidence of metamizole-
induced agranulocytosis (MIA) [47, 48]. However, recent
literature reported a very limited incidence of approxi-
mately 0.5 to 1 MIA case per million per year [22, 49–52].
From this it is concluded that the absolute risk of serious
adverse effects (including MIA) after postoperative treat-
ment with metamizole is probably much lower than the
absolute risk of serious adverse effects after treatment
with NSAIDs.
This study also aims to provide data on QOR at differ-
ent time points after four types of day surgery, each
known to have a high incidence of poor QOR at the
fourth postoperative day [3].
There are several instruments for assessing the inter-
mediate (4 to 7 days) and late (1 month) QOR after day
surgery, including the Functional Recovery Index (FRI)
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and Global Surgery Recovery (GSR) index [1, 2, 31]. Also,
quality of life questionnaires may fulfill the requirements
as useful indicators of surgical recovery [4]. However, so
far there is no general agreement on the optimal instru-
ments for evaluating recovery and outcome following
ambulatory surgery [53]. In our opinion, the FRI is the best
instrument for evaluating QOR at home after day surgery.
In our study we will apply three different instruments to
assess QOR: the Global Surgical Recovery index (GSR), the
FRI and the quality of life questionnaire EQ-5D. QOR will
be assessed at days 1, 2, 3, 4, 7, 14 and 28 postoperatively.
In conclusion, this trial aims to test the non-inferiority
of the analgesic power of a combination of metamizole
and paracetamol compared to a combination of ibupro-
fen and paracetamol after painful day surgery. This study
may also provide an insight into the QOR profile after
four different types of surgery and into the interrelation-
ship between the three different instruments used to
assess QOR.
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